Company intelligence / Profile preview

Hexacath

Ownership: Private
Employees: ~40
Development stage: Commercial

Overview

Hexacath has developed and commercialized the TiTAN OPTIMAX bioactive stent, which has demonstrated clinical superiority in acute coronary syndrome patients compared to drug-eluting stents. The company also markets the RayFlow microcatheter for assessing and treating coronary microvascular dysfunction. Their products are supported by nearly two decades of pre-clinical and clinical evidence.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on Hexacath.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hexacath.

Explore the full profile